MNPR
Monopar Therapeutics Inc
NASDAQ · Biotechnology
$57.75
+0.87 (+1.53%)
Open$57.92
Previous Close$56.88
Day High$61.20
Day Low$57.45
52W High$105.00
52W Low$26.06
Volume—
Avg Volume304.9K
Market Cap385.92M
P/E Ratio—
EPS$-3.44
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-28.5% upside
Current
$57.75
$57.75
Target
$41.31
$41.31
$22.89
$41.31 avg
$45.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 251.96M | 240.93M | 249.50M |
| Net Income | -49,856,785 | -48,544,141 | -56,777,530 |
| Profit Margin | -19.8% | -20.2% | -22.8% |
| EBITDA | -96,691,861 | -80,803,710 | -82,101,366 |
| Free Cash Flow | -37,656,070 | -41,639,536 | -51,685,705 |
| Rev Growth | +2.3% | +24.0% | -9.1% |
| Debt/Equity | 0.25 | 0.23 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |